<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5655D9DF-B87F-409E-9BD2-8CE1BDC910C3"><gtr:id>5655D9DF-B87F-409E-9BD2-8CE1BDC910C3</gtr:id><gtr:name>Cresset Biomolecular Discovery Limited</gtr:name><gtr:address><gtr:line1>Biopark Hertfordshire
Broadwater Road</gtr:line1><gtr:city>Welwyn Garden City</gtr:city><gtr:postCode>AL7 3AX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5655D9DF-B87F-409E-9BD2-8CE1BDC910C3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>5655D9DF-B87F-409E-9BD2-8CE1BDC910C3</gtr:id><gtr:name>Cresset Biomolecular Discovery Limited</gtr:name><gtr:address><gtr:line1>Biopark Hertfordshire
Broadwater Road</gtr:line1><gtr:city>Welwyn Garden City</gtr:city><gtr:postCode>AL7 3AX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>25000.0</gtr:offerGrant><gtr:projectCost>42516.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700618"><gtr:id>F8FA21B2-0CB3-4DE0-BA0C-AD8E6A69C80C</gtr:id><gtr:title>Market research to validate the commercial potential for a novel application that connects a multi-platform GUI to cloud-based infrastructure, to enable the rational structurebased design of new compounds for pharmaceutical R&amp;amp;D</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700618</gtr:grantReference><gtr:abstractText>The availability of crystallographic information for protein targets of pharmaceutical interest
has dramatically increased in the recent years, even for those targets, such as Trans-membrane
Receptors and Ion Channels, which until recently were considered extremely hard to
crystallise. The availability and cost of high-performing computing through cloud-based
infrastructure has also dramatically improved in the recent years. This has made the
application of complex drug design methods and algorithms to the study of complex targetligand
interactions accessible to pharmaceutical researchers.
Cresset have an existing suite of software tools aimed at helping both computational and
medicinal chemists with the design and synthesis of molecules, particularly helping with the
understanding of the 3D properties of the molecules and their interactions with target proteins;
however it is our belief that there is an increasing need for new tools to facilitate a rapid
utilization of cloud-resources in platform-independent desktop applications.
We intend to carry out market research in this area to validate our belief that a new software
application, that integrates cloud resources with a traditional interactive GUI for structurebased
design, will provide a paradigm shift in the speed of new molecule design and in the
exploitation of available crystallographic information on protein targets of pharmaceutical
interest.
We believe there is a significant worldwide market opportunity for such a tool, but we
strongly need to validate our concept with broader market data than we have been able to
access from our current customer contacts.</gtr:abstractText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>25000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700618</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>